IL-6信号调控GLP-1分泌:随机安慰剂对照研究
该多中心双盲试验将2型糖尿病或肥胖患者随机分配至托珠单抗、西格列汀或双安慰剂组,进行12周训练干预。结果显示,托珠单抗使急性运动时活性GLP-1水平降低26%,西格列汀使活性GLP-1水平升高53%;训练后西格列汀组混合餐试验中活性GLP-1 AUC约为安慰剂组两倍,而托珠单抗组停药4周后GLP-1 AUC呈非显著降低13%。结论提示IL-6参与人体GLP-1调控。
要点
- IL-6受体拮抗剂托珠单抗可降低运动及混合餐后活性GLP-1水平。
- 西格列汀显著升高活性GLP-1水平及混合餐试验AUC。
- 托珠单抗对GLP-1的影响在停药后 reversible,无持续效应。
核心结论
- IL-6参与人体GLP-1分泌调控,IL-6受体阻断可可逆性降低餐后及运动诱导的活性GLP-1水平。
研究设计与样本
- 多中心、双盲、随机安慰剂对照试验,纳入2型糖尿病或肥胖患者,随机分配至静脉托珠单抗8 mg/kg每4周、口服西格列汀100 mg每日或双安慰剂组,进行12周训练干预。
主要发现
- 急性运动时,托珠单抗组活性GLP-1水平较安慰剂组低26%(乘性效应0.74 [95% CI 0.56, 0.98],p=0.034)。
- 急性运动时,西格列汀组活性GLP-1水平较安慰剂组高53%(1.53 [1.15, 2.03],p=0.004)。
- 12周训练后,西格列汀组混合餐试验活性GLP-1 AUC约为安慰剂组两倍(2.03 [1.56, 2.62],p<0.001)。
- 末次托珠单抗输注后4周,GLP-1 AUC较安慰剂组非显著降低13%(0.87 [0.67, 1.12],p=0.261)。
临床怎么用
- 使用IL-6受体拮抗剂托珠单抗时,需注意其可能降低运动及餐后活性GLP-1水平,但停药后效应可逆。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: IL-6 is a cytokine with various effects on metabolism. In mice, IL-6 improved beta cell function and glucose homeostasis via upregulation of glucagon-like peptide 1 (GLP-1), and IL-6 release from muscle during exercise potentiated this beneficial increase in GLP-1. This study aimed to identify whether exercise-induced IL-6 has a similar effect in humans. METHODS: In a multicentre, double-blind clinical trial, we randomly assigned patients with type 2 diabetes or obesity to intravenous tocilizumab (an IL-6 receptor antagonist) 8 mg/kg every 4 weeks, oral sitagliptin (a dipeptidyl peptidase-4 inhibitor) 100 mg daily or double placebos (a placebo saline infusion every 4 weeks and a placebo pill once daily) during a 12 week training intervention. The primary endpoints were the difference in change of active GLP-1 response to an acute exercise bout and change in the AUC for the concentration-time curve of active GLP-1 during mixed meal tolerance tests at baseline and after the training intervention. RESULTS: Nineteen patients were allocated to tocilizumab, 17 to sitagliptin and 16 to placebos. During the acute exercise bout active GLP-1 levels were 26% lower with tocilizumab (multiplicative effect: 0.74 [95% CI 0.56, 0.98], p = 0.034) and 53% higher with sitagliptin (1.53 [1.15, 2.03], p = 0.004) compared with placebo. After the 12 week training intervention, the active GLP-1 AUC with sitagliptin was about twofold that with placebo (2.03 [1.56, 2.62]; p < 0.001), while GLP-1 AUC values showed a small non-significant decrease of 13% at 4 weeks after the last tocilizumab infusion (0.87 [0.67, 1.12]; p = 0.261). CONCLUSIONS/INTERPRETATION: IL-6 is implicated in the regulation of GLP-1 in humans. IL-6 receptor blockade lowered active GLP-1 levels in response to a meal and an acute exercise bout in a reversible manner, without lasting effects beyond IL-6 receptor blockade. TRIAL REGISTRATION: Clinicaltrials.gov NCT01073826. FUNDING: Danish National Research Foundation. Danish Council for Independent Research. Novo Nordisk Foundation. Danish Centre for Strategic Research in Type 2 Diabetes. European Foundation for the Study of Diabetes. Swiss National Research Foundation.
引用
- Ellingsgaard H, Seelig E, Timper K, et al. GLP-1 secretion is regulated by IL-6 signalling: a randomised, placebo-controlled study. Diabetologia. 2019. PMID: 31796986. doi:10.1007/s00125-019-05045-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。